The potential of circulating free DNA of methylated IGFBP as a biomarker for type 2 diabetes Mellitus: A Comprehensive review
- 18 December 2024
- journal article
- review article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 567, 120104
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Systematically Evaluating Cell‐Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation PatternsAdvanced Science, 2024
- Cell-free DNA in maternal blood and artificial intelligence: accurate prenatal detection of fetal congenital heart defectsAmerican Journal of Obstetrics and Gynecology, 2022
- Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmationAmerican Journal of Obstetrics and Gynecology, 2022
- Proteome-wide assessment of diabetes mellitus in Qatari identifies IGFBP-2 as a risk factor already with early glycaemic disturbancesArchives of Biochemistry and Biophysics, 2020
- Multi-layered epigenetic regulation of IRS2 expression in the liver of obese individuals with type 2 diabetesDiabetologia, 2020
- Association between cell‐free DNA fetal fraction and gestational diabetesPrenatal Diagnosis, 2020
- Rapid Preparation of a Plasma Membrane Fraction: Western Blot Detection of Translocated Glucose Transporter 4 from Plasma Membrane of Muscle and Adipose Cells and TissuesCurrent Protocols in Protein Science, 2016
- First‐trimester combined screening for trisomy 21 at 7–14 weeks' gestationUltrasound in Obstetrics & Gynecology, 2010
- The role of insulin‐like growth factor‐I and its binding proteins in glucose homeostasis and type 2 diabetesDiabetes/Metabolism Research and Reviews, 2009
- The thrifty epigenotype: An acquired and heritable predisposition for obesity and diabetes?BioEssays, 2008